T-Net: Home

Member Login
|
Employer Login

BC Tech News ▼
International ▼
Member Tools ▼
- Subscribe to T-Net Direct
Submit News ▼

« Sections »
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
« Account Login »
Members
Employers
« Services »
Post Job Listings
Browse Jobs
Advertise

News By Company

Aurinia Pharmaceuticals Inc.

1 - 10 of 49 Results

New Search

Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS (Voclosporin), Receives 15 Years of Drug Exclusivity Protection (Orphan Drug)

Victoria, BC, May 10, 2023--Aurinia Pharmaceuticals Inc. announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization of LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy to treat adults with active class III, IV and V (including mixed classes III/V and IV/V) lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE).

Snapshot | Profile | News (54) | Follow

Company Snapshot

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)
20-49 Employees In BC (20-49 Employees Total)
Founded: 2013

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results, Q1 Revenue up 59% YoY to US $34.4 Million

Victoria, BC, May 8, 2023--Aurinia Pharmaceuticals Inc. issued its financial results for first quarter ended March 31, 2023. Total net revenue was $34.4 million for the quarter ended March 31, 2023, compared to $21.6 million in the prior year quarter ended March 31, 2022, representing significant growth of 59% year over year. T

Snapshot | Profile | News (54) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS in the Treatment of Lupus Nephritis Issued by United States

Victoria, BC, April 26, 2023--Aurinia Pharmaceuticals Inc. announced that the United States Patent and Trademark Office (USPTO) has issued a new and refined method of use patent titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinia's newly issued U.S. Patent (No. 11,622,991) reflects the unique and proprietary dosing regimen of its currently marketed product, LUPKYNIS.

Snapshot | Profile | News (54) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial

Victoria, BC, April 18, 2023--Aurinia Pharmaceuticals Inc. has announced promising results from the AURORA Renal Biopsy Sub-Study. LUPKYNIS is a novel agent approved for the treatment of adults with active lupus nephritis (LN).

Snapshot | Profile | News (54) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Announces US Patent Trial and Appeal Board Has Terminated the Inter Partes Review of it's U.S. Patent No. 10,286,036

Victoria, BC, February 2, 2023--Aurinia Pharmaceuticals Inc. (Aurinia) announces that the Patent Trial and Appeal Board (PTAB) of the United States' Patent and Trademark Office has terminated the Inter Partes Review (IPR) it had instituted with respect to Aurinia's U.S. Patent No. 10,286,036.

Snapshot | Profile | News (54) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Pharmaceuticals Announces Allowance of New and Refined 'Method of Use' Patent for LUPKYNIS From US Patent and Trademark Office

Victoria, BC, January 27, 2023--Aurinia Pharmaceuticals Inc. (Aurinia or the Company) announced that the United States Patent and Trademark Office (USPTO) has allowed a method of use patent application titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS.

Snapshot | Profile | News (54) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Provides Strong Preliminary Q4 and Full-year 2022 Net Revenue Results (Revenue of $134M, and Cash and Investments of $134M)

Victoria, BC, January 9, 2023--Aurinia Pharmaceuticals Inc. (Aurinia or the Company) provided an update on its business performance. Preliminary unaudited net revenue for the three months and full year ended December 31, 2022 was approximately $28.4 million and $134.0 million.

Snapshot | Profile | News (54) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Victoria-based Aurinia Reaches Patent Challenge Settlement With Sun Pharmaceuticals, Stock Soars 56% on Settlement / M&A Speculation

Victoria, BC, January 4, 2023--Aurinia Pharmaceuticals announced today that it has entered into a settlement agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE (collectively, Sun Pharmaceuticals).

Snapshot | Profile | News (54) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis

Victoria, BC, December 7, 2022--Aurinia Pharmaceuticals Inc. , a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted the Great Britain marketing authorization of LUPKYNIS (voclosporin) to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE).

Snapshot | Profile | News (54) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Aurinia Receives $30 Million Milestone Payment, European Commission Approval of its Drug for the Treatment of Lupus Nephritis

Victoria, BC, September 29, 2022--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced that the European Commission (EC) has granted marketing authorization of LUPKYNIS (voclosporin) to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE).

Snapshot | Profile | News (54) | Follow

Company Snapshot

See Full Profile

Company Alert

Aurinia Pharmaceuticals Inc.

Victoria (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

1 2 3 4 5

Hiring Today

See All Jobs

Latest Tech Jobs

Featured Job: Manager, NetSuite ERP

Global Relay Communications Inc.

Dev Ops Specialist

BC Public Service

Marketing Leader, Precision NanoSystems

Precision NanoSystems, Inc.

Senior Cyber Security Architect

MDA

Senior Director, Go-To-Market Strategy

Kabam Games Inc.

See All Jobs

Registration on or use of this website constitutes acceptance of our Terms of Use.

News
BC Tech News ▼
- Local BC Tech News
- One Week View
- Subscribe to T-Net Direct
International ▼
- All Breaking International Tech News
- Tech Crunch
- Silicon Alley Insider
- VentureBeat
- CNET
Member Tools ▼
- Subscribe to T-Net Direct
Submit News ▼
- Post News Release on T-Net
- Submit Anonymous News Tip
- T-Net News Submission Guidelines
Account
Member Login
Employer Login
Sections
News
- BC Tech News ▼
- International ▼
- Member Tools ▼
  - Subscribe to T-Net Direct
- Submit News ▼
Events
- All BC Tech Events ▼
- Member Tools ▼
- Post Events ▼
Tech Careers
- Tech Careers Home
- Job Search ▼
- Hot Job of the Week TM
- Post Resume ▼
  - Post Resume
  - Create Cover Letter
- Member Tools ▼
- Employers ▼
  - Employer Login
  - Post New Job
Directory
- Tech Directory Home
- Companies ▼
- Suppliers ▼
- Associations ▼
- Add Profile ▼
Tech Stocks
- BC Tech Stocks ▼
- T-Net 20 Stock Index
- Member Tools ▼
  - Stock Alerts
  - Company Search
- Add Company ▼
  - Add Company
T-Net 100
- T-Net 100 Rankings ▼
- Sector Rankings ▼
- Advertising
Members
- Member Home ▼
- News ▼
- Events ▼
- Careers ▼
- Directory ▼
- Other ▼
Feedback
About T-Net
Services
Post Job Listings
Advertise on T-Net